Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: bisphosphonate

Routine Osteoporosis Screening in Men Proves Cost-Effective

Shannon Aymes  |  

NEW YORK (Reuters Health)—Routine osteoporosis screening in men is a good value and effective based on a cost-effectiveness model, researchers say. “Osteoporosis is not just a disease for women. Osteoporosis affects many men (approximately 2 million in the U.S.), with significant morbidity, mortality, and costs that are projected to rise with the aging of the…

Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

Alessandro Villa, DDS, PhD, MPH, & Sook Bin Woo, DMD, MMSc  |  

Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

New Labeling for Infused Golimumab; Phase 3 Trial for Romosozumab Promising

  |  

The FDA has approved new labeling for infused golimumab to include measures of mental and physical health. Plus romosozumab meets primary endpoints in postmenopausal women with osteoporosis during a Phase 3 trial…

Serum IGF-1 Tied to Fracture Risk in Elderly Women

David Douglas  |  

NEW YORK (Reuters Health)—A Dutch study confirms that reduced serum levels of insulin-like growth factor-1 (IGF-1) are associated with increased fracture risk in elderly women, but not men. In an Aug. 31 online paper in the Journal of Clinical Endocrinology & Metabolism, Dr. N.C. van Varsseveld, of VU University Medical Center, Amsterdam, and colleagues noted that…

Did Reports of Side Effects Contribute to Drop in Bone Drug Use?

Lisa Rapaport  |  

(Reuters Health)—Media reports raising safety concerns about osteoporosis drugs known as bisphosphonates may have contributed to a sharp drop in their use—even though U.S. doctors and drug regulators haven’t recommended against taking them, a study suggests. Fosamax (alendronate sodium) won U.S. marketing approval in 1995. Widespread use of the drug and others like it over…

Teriparatide to Denosumab Switch Helpful in Osteoporosis

David Douglas  |  

NEW YORK (Reuters Health)—In postmenopausal osteoporotic women, changing from teriparatide to denosumab benefits bone mineral density (BMD) but switching from denosumab to teriparatide may result in bone loss, according to new research. In a July 3 online paper in The Lancet, Dr. Benjamin Z. Leder, of Massachusetts General Hospital, Boston, and colleagues noted that many…

The ACR’s State-of-the-Art Clinical Symposium: Rheumatologists Weigh in on Tough-to-Treat Cases, Paget’s Disease, Imaging

  |  

CHICAGO—A 49-year-old woman has had RA for eight years. She has a rheumatoid factor reading of 35, an aCCP reading of 160, erythrocyte sedimentation rate of 42, plus erosions. She has been on methotrexate. She tried etanercept for six months, but then it stopped working. She was on 40 mg of adalimumab weekly, but it…

HIV Infection: What Rheumatologists Need to Know

HIV Infection: What Rheumatologists Need to Know

Leonard H. Calabrese, DO, & Elizabeth Kirchner, MSN, CNP  |  

It has been nearly 35 years since the original descriptions of what now is recognized as AIDS (the acquired immune deficiency syndrome), an advanced form of infection secondary to the human immunodeficiency virus (HIV). The epidemic of HIV infection remains the singular most dramatic epidemic of our generation and will likely remain with us for…